STOKE THERAPEUTICS INC's ticker is STOK and the CUSIP is 86150R107. A total of 108 filers reported holding STOKE THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $42 | -62.5% | 10,688 | +1.2% | 0.00% | – |
| Q2 2023 | $112 | -6.7% | 10,566 | -26.6% | 0.00% | – |
| Q1 2023 | $120 | -9.8% | 14,398 | 0.0% | 0.00% | – |
| Q4 2022 | $133 | -99.9% | 14,398 | +0.0% | 0.00% | – |
| Q3 2022 | $185,000 | -2.1% | 14,395 | +0.5% | 0.00% | – |
| Q2 2022 | $189,000 | -37.6% | 14,329 | -0.3% | 0.00% | – |
| Q1 2022 | $303,000 | -11.9% | 14,375 | +0.1% | 0.00% | – |
| Q4 2021 | $344,000 | -18.5% | 14,358 | -13.5% | 0.00% | – |
| Q3 2021 | $422,000 | -24.1% | 16,601 | +0.6% | 0.00% | -100.0% |
| Q2 2021 | $556,000 | +8.4% | 16,507 | +25.1% | 0.00% | 0.0% |
| Q1 2021 | $513,000 | -25.3% | 13,200 | +18.9% | 0.00% | 0.0% |
| Q4 2020 | $687,000 | +84.7% | 11,100 | 0.0% | 0.00% | – |
| Q3 2020 | $372,000 | +40.4% | 11,100 | 0.0% | 0.00% | – |
| Q2 2020 | $265,000 | +20.5% | 11,100 | +15.6% | 0.00% | – |
| Q1 2020 | $220,000 | -19.1% | 9,600 | 0.0% | 0.00% | – |
| Q4 2019 | $272,000 | +32.0% | 9,600 | 0.0% | 0.00% | – |
| Q3 2019 | $206,000 | – | 9,600 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ATP Life Science Ventures, L.P. | 17,161,713 | $666,561,000 | 74.20% |
| RTW INVESTMENTS, LP | 3,644,248 | $141,543,000 | 2.21% |
| Redmile Group, LLC | 2,544,062 | $98,811,000 | 1.39% |
| Cormorant Asset Management, LP | 1,437,807 | $55,844,000 | 1.24% |
| ACUTA CAPITAL PARTNERS, LLC | 45,000 | $1,748,000 | 0.63% |
| SPHERA FUNDS MANAGEMENT LTD. | 150,729 | $5,854,000 | 0.45% |
| HighVista Strategies LLC | 13,692 | $532,000 | 0.40% |
| Birchview Capital, LP | 15,000 | $583,000 | 0.35% |
| Perceptive Advisors | 671,978 | $26,100,000 | 0.33% |
| GILDER GAGNON HOWE & CO LLC | 1,265,950 | $49,169,000 | 0.26% |